- Home
- APPS vs TYRA Comparison
APPS vs TYRA Comparison
Compare APPS & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- TYRA
- Stock Information
- Founded
- APPS N/A
- TYRA 2018
- Country
- APPS United States
- TYRA United States
- Employees
- APPS N/A
- TYRA N/A
- Industry
- APPS Multi-Sector Companies
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- APPS Miscellaneous
- TYRA Health Care
- Exchange
- APPS Nasdaq
- TYRA Nasdaq
- Market Cap
- APPS 562.7M
- TYRA 571.9M
- IPO Year
- APPS N/A
- TYRA 2021
- Fundamental
- Price
- APPS $4.49
- TYRA $11.79
- Analyst Decision
- APPS Buy
- TYRA Strong Buy
- Analyst Count
- APPS 3
- TYRA 8
- Target Price
- APPS $4.83
- TYRA $31.00
- AVG Volume (30 Days)
- APPS 2.7M
- TYRA 227.0K
- Earning Date
- APPS 11-05-2025
- TYRA 11-06-2025
- Dividend Yield
- APPS N/A
- TYRA N/A
- EPS Growth
- APPS N/A
- TYRA N/A
- EPS
- APPS N/A
- TYRA N/A
- Revenue
- APPS $503,443,000.00
- TYRA N/A
- Revenue This Year
- APPS $10.64
- TYRA N/A
- Revenue Next Year
- APPS $11.24
- TYRA N/A
- P/E Ratio
- APPS N/A
- TYRA N/A
- Revenue Growth
- APPS N/A
- TYRA N/A
- 52 Week Low
- APPS $1.18
- TYRA $6.42
- 52 Week High
- APPS $7.77
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- APPS 51.11
- TYRA 51.81
- Support Level
- APPS $4.09
- TYRA $11.89
- Resistance Level
- APPS $4.62
- TYRA $12.91
- Average True Range (ATR)
- APPS 0.25
- TYRA 0.77
- MACD
- APPS 0.08
- TYRA -0.03
- Stochastic Oscillator
- APPS 83.93
- TYRA 55.64
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.